Hopitaux Universitaires Paris Centre-Hopital Cochin

Verified siteinfo

France 123 Bd de Port Royal, Batiment Copernic 5eme etage Service Oncologie, Paris, Paris, France,, 75014 Paris, France

4 trials recruiting
Non-small cell lung cancer · Abortion threatened · Chronic obstructive pulmonary disease
Adult patients

About Specializations

Hopitaux Universitaires Paris Centre-Hopital Cochin in Paris, France specialises in clinical trials of conditions such as Non-small cell lung cancer, Abortion threatened, Chronic obstructive pulmonary disease, Fallopian tube cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, with a particular focus on non-small cell lung cancer (NSCLC). The institution is dedicated to advancing treatment options for patients with RET fusion-positive NSCLC, a subtype characterized by specific genetic alterations.

Advanced or Metastatic RET Fusion-Positive NSCLC
Targeted Therapies
Precision Medicine

Through its research, the center is contributing to the development of novel therapeutic strategies, such as the use of selpercatinib, which is being compared to traditional platinum-based therapies in clinical trials. This work is pivotal in enhancing the efficacy and personalization of cancer treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

123 Bd de Port Royal, Batiment Copernic 5eme etage Service Oncologie, Paris, Paris, France,75014 ParisFrance

Open in maps ↗

Recruiting now: 4 trials
Conditions studied: 7
Partner status: Verified site

More sites in Paris France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

6 clinical trials

Chronic obstructive pulmonary disease

Recruiting

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational

France

Participants:18–64 years · 65+ years
Substances:PF-07275315
Sponsor:Pfizer Inc.

Contact Research Centre

Fallopian tube cancer+2

Recruiting

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

Non-small cell lung cancer

Recruiting

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Pfizer Inc.

Contact Research Centre

Pleural mesothelioma

Recruiting

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Abortion threatened

Not yet recruiting

Comparison of ceftriaxone and azithromycin versus amoxicillin and azithromycin for pregnant women with preterm premature rupture of membranes between 22 and 33 weeks.

Registered drugNo placebo